Provided by Tiger Trade Technology Pte. Ltd.

MAIA Biotechnology Inc.

1.39
+0.09006.92%
Post-market: 1.400.0100+0.72%19:30 EDT
Volume:799.18K
Turnover:1.09M
Market Cap:84.33M
PE:-2.28
High:1.40
Open:1.30
Low:1.30
Close:1.30
52wk High:3.19
52wk Low:0.8700
Shares:60.67M
Float Shares:55.61M
Volume Ratio:1.96
T/O Rate:1.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6085
EPS(LYR):-0.7000
ROE:-218.68%
ROA:-92.10%
PB:4.08
PE(LYR):-1.99

Loading ...

Maia Biotechnology Director Ramiro Guerrero Acquires 37,595 Common Shares Worth $49,511.38

Reuters
·
Yesterday

MAIA Biotechnology Presents Next-Generation Telomere-Targeting Cancer Drug Candidates at IRT 2026

Reuters
·
Sep 10

Maia Bio Director Ramiro Guerrero Buys 133,790 Shares Worth $185,114.90

Reuters
·
Sep 02

Maia Bio Director Ramiro Guerrero Acquires 1,794 Common Shares Worth $2,386.02

Reuters
·
Aug 26

Maia Biotechnology Director Ramiro Guerrero Reports Purchase of 11,899 Common Shares for $16,301.63

Reuters
·
Aug 25

MAIA Biotechnology files $150M mixed securities shelf

TIPRANKS
·
Aug 22

MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate

Benzinga Earnings
·
Aug 10

Maia Biotech Q2 FY26 Net Loss Widens 49% to $7.94 Million

Reuters
·
Aug 10

Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA)

TIPRANKS
·
Jul 10

Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr in 3l Nsclc

Reuters
·
Jul 08

MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion

TIPRANKS
·
Jul 08

Maia Biotech Reports 90.5% Disease Control Rate in Phase 2 Third-line NSCLC Trial Expansion

Reuters
·
Jul 08

Maia Biotechnology - Ateganosine Plus Cemiplimab Shows Acceptable Safety Profile in Heavily Pre-treated Patients

THOMSON REUTERS
·
Jul 08

Maia Biotechnology Reports Strong Initial Efficacy Data in Third-line Non-small Cell Lung Cancer from Phase 2 Thio-101 Part C Expansion Trial

THOMSON REUTERS
·
Jul 08

Maia Biotechnology - Thio-101 Part C Shows 90.5% Disease Control Rate in 3L Nsclc

THOMSON REUTERS
·
Jul 08

Maia Biotechnology - Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr in 3L Nsclc

THOMSON REUTERS
·
Jul 08

Maia Biotechnology Completes International Enrollment in Part C of Phase 2 Thio-101 Expansion Trial in Third-line Non-small Cell Lung Cancer

THOMSON REUTERS
·
Jun 25

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

GlobeNewswire
·
Jun 25

Maia Biotech opens enrollment at Emory Winship for Phase 2 ateganosine NSCLC trial

Reuters
·
Jun 18

Maia Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

THOMSON REUTERS
·
Jun 18